{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:08:05Z","timestamp":1760954885059},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Von Willebrand disease (VWD) diagnosis and classification usually require a combination of nonspecific and VW-factor (VWF)-specific assays. We evaluated the analytical performance of a commercially available collagen-binding assay (CBA) and its usefulness in conjunction with other assays for laboratory diagnosis of VWD.<\/jats:p>\n               <jats:p>Methods: We used a commercial CBA ELISA (Life Technologies) to evaluate 3085 plasma samples. We used standard procedures to perform other assays, including factor VIII activity (FVIII:C), VWF antigen (VWF:Ag), ristocetin cofactor activity, VWF collagen binding capacity (VWF:CB), and VWF multimeric analysis.<\/jats:p>\n               <jats:p>Results: CBA intra- and interassay CVs were &amp;lt;6% and &amp;lt;13%, respectively. Reference intervals were 45%\u2013198% for VWF:CB and 0.75\u20131.32 for the VWF:CB\/Ag ratio. Of 3085 samples tested, 235 (8%) had results commonly associated with VWD. Multimer analysis and phenotypic data in 156 samples identified VWD types as: 91 (58%) type 1, 62 (40%) type 2, and 3 (2%) type 3. Of the 91 type 1 samples, proportional decreases in functional activity were seen in 75 samples (82%) according to CBA and in 63 samples (69%) according to the ristocetin cofactor assay. Of the type 2 samples, 10 were further identified as probable type 2A, 26 as probable type 2B, 12 as probable type 2M, and 14 could not be subtyped. VWF:CBA\/Ag ratios &amp;lt;0.5 occurred in 83% of VWD type 2A and 2B samples, indicating characteristic functional discordance. Mean (SD) VWF:CB values were significantly higher in individuals without group O blood [113 (45)] than in those with group O blood [83 (32)] (t-test, P = 0.007).<\/jats:p>\n               <jats:p>Conclusions: The commercial CBA assay produces reliable results and is useful for laboratory diagnosis of VWD.<\/jats:p>","DOI":"10.1373\/clinchem.2006.070730","type":"journal-article","created":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T20:34:22Z","timestamp":1154637262000},"page":"1965-1967","source":"Crossref","is-referenced-by-count":12,"title":["Performance and Clinical Utility of a Commercial von Willebrand Factor Collagen Binding Assay for Laboratory Diagnosis of von Willebrand Disease"],"prefix":"10.1093","volume":"52","author":[{"given":"Joanna","family":"Popov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Zhukov","sequence":"first","affiliation":[{"name":"Coagulation Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Ruden","sequence":"first","affiliation":[{"name":"Coagulation Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Zeschmann","sequence":"first","affiliation":[{"name":"Coagulation Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Sferruzza","sequence":"first","affiliation":[{"name":"Coagulation Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervyn","family":"Sahud","sequence":"first","affiliation":[{"name":"Coagulation Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,10,1]]},"reference":[{"key":"2020022801233693000_R1","doi-asserted-by":"crossref","unstructured":"Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Bouyljenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost2000;84:160-174.","DOI":"10.1055\/s-0037-1613992"},{"key":"2020022801233693000_R2","doi-asserted-by":"crossref","unstructured":"Sadler JE, Rodeghiero F. ISTH SSC Subcommittee on von Willebrand Factor: provisional criteria for the diagnosis of VWD Type 1. J Thromb Haemost2005;3:775-777.","DOI":"10.1111\/j.1538-7836.2005.01245.x"},{"key":"2020022801233693000_R3","doi-asserted-by":"crossref","unstructured":"Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. Semin Thromb Hemost2002;28:191-202.","DOI":"10.1055\/s-2002-27821"},{"key":"2020022801233693000_R4","doi-asserted-by":"crossref","unstructured":"Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost2000;83:127-135.","DOI":"10.1055\/s-0037-1613768"},{"key":"2020022801233693000_R5","doi-asserted-by":"crossref","unstructured":"Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A. Type 2M von Willebrand disease variant characterized by abnormal von Willebrand factor multimerization. J Lab Clin Med2001;137:70-76.","DOI":"10.1067\/mlc.2001.111252"},{"key":"2020022801233693000_R6","doi-asserted-by":"crossref","unstructured":"Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH. Use of collagen binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol2002;116:187-192.","DOI":"10.1046\/j.1365-2141.2002.03199.x"},{"key":"2020022801233693000_R7","doi-asserted-by":"crossref","unstructured":"Casonato A, Pontara E, Bertomoro A, Sartorelli F, Cattini MG, Girolamo A. Von Willebrand factor collagen binding activity in diagnosis of von Willebrand disease: an alternative to ristocetin cofactor activity?. Br J Haematol2001;112:578-583.","DOI":"10.1046\/j.1365-2141.2001.02597.x"},{"key":"2020022801233693000_R8","doi-asserted-by":"crossref","unstructured":"Favoloro EJ, Soltani S, McDonald J. Potential laboratory misdiagnosis of hemophilia and von Willebrand disorders owing to cold activation of blood sample for testing. Am J Clin Pathol2004;122:686-692.","DOI":"10.1309\/E4947DG48TVY19C2"},{"key":"2020022801233693000_R9","doi-asserted-by":"crossref","unstructured":"Baronciani L, Federici AB, Beretta M, Cozzi G, Canciani MT, Manucci PM. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost2005;3:2689-2694.","DOI":"10.1111\/j.1538-7836.2005.01638.x"},{"key":"2020022801233693000_R10","doi-asserted-by":"crossref","unstructured":"Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost2003;1:2191-2197.","DOI":"10.1046\/j.1538-7836.2003.00367.x"},{"key":"2020022801233693000_R11","doi-asserted-by":"crossref","unstructured":"Favaloro EJ, Soltani S, Mc Donald J, Grezchnik E, Easton L, Favaloro JWC. Reassessment of ABO-blood group, gender, and age on laboratory parameters used to diagnose von Willebrand Disorder (VWD): potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol2005;124:910-917.","DOI":"10.1309\/W76QF806CE80CL2T"},{"key":"2020022801233693000_R12","doi-asserted-by":"crossref","unstructured":"Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Thom J, Baker R, . on behalf of the Royal College Of Pathologists Of Australasia Quality Assurance Program In Hematologyet al. Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates. Lab Hematol2005;11:91-97.","DOI":"10.1532\/LH96.04063"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/10\/1965\/32687429\/clinchem1965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/10\/1965\/32687429\/clinchem1965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T01:24:21Z","timestamp":1582853061000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/52\/10\/1965\/5626646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,1]]},"references-count":12,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2006,10,1]]},"published-print":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.070730","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,10,1]]},"published":{"date-parts":[[2006,10,1]]}}}